论文部分内容阅读
目的:探讨美托洛尔联合曲美他嗪对急诊冠心病心力衰竭患者心功能及预后的影响。方法:回顾性分析2013年1月-2014年12月本院诊治的112例急诊冠心病患者临床资料,按照不同治疗方案分为两组(每组56例),对照组行常规治疗,研究组在对照组基础上给予美托洛尔+曲美他嗪治疗,观察并比较两组临床疗效、心功能、血脂指标改善情况及预后。结果:研究组临床治疗有效率比对照组高(P<0.05);两组治疗后心功能及血脂指标均较治疗前明显改善,且研究组改善幅度更显著(P<0.05,P<0.01);两组预后情况均较佳,用药不良反应率均较低但无统计学差异(P>0.05)。结论:美托洛尔联合曲美他嗪对急诊冠心病心力衰竭心功能及预后均具积极影响,可以增强临床疗效,且改善预后,值得临床推广及应用。
Objective: To investigate the effect of metoprolol combined with trimetazidine on cardiac function and prognosis in patients with heart failure of coronary heart disease. Methods: The clinical data of 112 patients with acute coronary heart disease diagnosed and treated in our hospital from January 2013 to December 2014 were retrospectively analyzed. The patients were divided into two groups (56 cases in each group) according to different treatment regimens. The control group received routine treatment. The study group Metoprolol + trimetazidine was given on the basis of the control group. The clinical curative effect, cardiac function, the improvement of the lipid index and the prognosis of the two groups were observed and compared. Results: The effective rate of clinical treatment in study group was higher than that in control group (P <0.05). The cardiac function and blood lipid of two groups were significantly improved after treatment, and the improvement rate of study group was more significant (P <0.05, P <0.01) The prognosis of the two groups were better, the rate of adverse reactions was lower but no significant difference (P> 0.05). Conclusion: Metoprolol combined with trimetazidine has a positive effect on cardiac function and prognosis of patients with acute coronary heart disease and heart failure, which can enhance clinical efficacy and improve prognosis, which is worthy of clinical promotion and application.